Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
10:52am, Monday, 24'th Jun 2024
Shares of Alnylam Pharmaceuticals rose by over 32%, the company's largest single-day gain in nearly two years, after announcing its drug vutrisiran helped reduce the number of deaths and cardiovascula
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
10:33am, Monday, 24'th Jun 2024
Heart disease drugmaker Alnylam (NASDAQ: ALNY ) stock rose sharply on the success of a Phase 3 study of its heart drug, vutrisiran. The drug is also sold as Amvuttra.
Cramer's Stop Trading: Alnylam Pharma
10:22am, Monday, 24'th Jun 2024
CNBC's Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
09:49am, Monday, 24'th Jun 2024
Monday, Alnylam Pharmaceuticals Inc ALNY revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyop
Alnylam Stock Soars After Positive Results From Heart Disease Study
08:30am, Monday, 24'th Jun 2024
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
08:09am, Monday, 24'th Jun 2024
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
07:51am, Monday, 24'th Jun 2024
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
Alnylam's heart disease drug meets main goal in late-stage study
07:08am, Monday, 24'th Jun 2024
Alnylam Pharmaceuticals said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutr
The 'Undercovered' Dozen From June 1-6
06:26pm, Friday, 07'th Jun 2024
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered al
June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge
06:14am, Wednesday, 05'th Jun 2024
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biote
Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
02:32pm, Monday, 03'rd Jun 2024
Alnylam Pharmaceuticals, Inc. is set to release clinical data from its HELIOS-B study in late June/early July, and this will have a significant impact on the company's share price. The success of the
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
01:31pm, Friday, 03'rd May 2024
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
12:15pm, Thursday, 02'nd May 2024
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President-Investor Relations and Corporat
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
11:07am, Thursday, 02'nd May 2024
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street
